Status:
TERMINATED
3T Perfluorocarbon-Filled Endorectal Magnetic Resonance Spectroscopic Imaging of Prostate
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborating Sponsors:
United States Department of Defense
GE Healthcare
Conditions:
Prostate Cancer
Eligibility:
MALE
18+ years
Phase:
NA
Brief Summary
Objectives: The objectives of this study are to: 1) evaluate the feasibility of 3T MRSI of prostate in improving the spectral resolution, using a PFC-filled endorectal coil, 2) develop a systematic m...
Detailed Description
Part 1: Prostate cancer tissue has certain differences in its metabolism (chemical makeup) that are not seen in normal tissue. MRSI is a type of magnetic resonance imaging (MRI) that uses the same ty...
Eligibility Criteria
Inclusion
- Biopsy proven, clinical stage 1-3 prostate carcinomas
- Prostatectomy at M. D. Anderson within 3 months from the time of MRSI
- An interval of \> 6 weeks between the biopsy and MRSI
- Signed informed consent form
Exclusion
- Contraindications for MRI (e.g. cardiac pacemaker)
- Contraindications for MRS (e.g. history of abdomino-perineal resection of rectum)
- Metals or any conditions (e.g. hip prosthesis) that can distort the local magnetic field
- Previous prostate surgery for prostate carcinoma (including, TURP and cryosurgery), local or systemic treatment for prostate carcinoma (e.g. radiation, androgen deprivation), pelvic radiation (e.g. rectal cancer), rectal surgery, BCG for bladder cancer
Key Trial Info
Start Date :
March 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 12 2019
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT00464724
Start Date
March 1 2007
End Date
December 12 2019
Last Update
February 10 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Texas MD Anderson Cancer Center
Houston, Texas, United States, 77030